Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
Source check: Source checked. Not independent scientific confirmation.
Finding / tested result: RNA-seq/clinical data from 553 TCGA samples are divided into training/validation cohorts; survival and ROC analyses are reported, without an external validation dataset.
Technology: LASSO and stepwise Cox models construct a cuproptosis-related lncRNA signature for prostate-cancer disease-free survival.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- LASSO and stepwise Cox models construct a cuproptosis-related lncRNA signature for prostate-cancer disease-free survival.
- Limitation / still unknown
- This is a retrospective prognostic association with no experimental mechanism validation; interpret as a cohort-specific signature.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://europepmc.org/article/MED/36717792 · https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_json/PMC9887873/unicode · https://pubmed.ncbi.nlm.nih.gov/36717792/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.